Project Grant R43HL174365
Award Date
9/20/24
Completion Date
9/19/25
Dollars Obligated
$400K
Federal Agency
National Heart Lung and Blood Institute
Federal Grant Program
93.837
Assistance Type
Project Grant
Place of Performance
Utah, USA
Similar Awards
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $2,095,816 Project Grant (CFDA 93.837 Cardiovascular Diseases Research) to The DNA Medicine Institute, Inc. to develop a 5-minute point-of-care test for measuring anti-Factor Xa activity and hemoglobin levels. This diagnostic tool aims to guide emergency management of patients on direct oral anticoagulants, enabling faster delivery of life-saving interventions such as andexanet alfa for bleeding or thrombolytics for acute ischemic...
The National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research (CFDA 93.837) program, awarded a $310,948 Project Grant to Minnesota Healthsolutions Corporation, a for-profit woman-owned small business, on September 15, 2023. The grant funds the development of an adaptable platform to support patients with behavior change interventions aimed at improving adherence to treatment and prevention for multiple chronic diseases. The platform will utilize remote...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $297,587 Project Grant (CFDA 93.837 - Cardiovascular Diseases Research) to General Fluidics Corporation to validate the performance of the AXESS system, a novel point-of-need clinical chemistry and hematology platform. The goal is to demonstrate equivalence between the AXESS system's results and those obtained from standard venous blood testing for a basic metabolic panel and complete blood count, using matched capillary and...
This $265,347 Project Grant was awarded by the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research (CFDA 93.837) federal grant program. The grant recipient, Functional Fluidics Inc., a minority-owned for-profit company in Detroit, Michigan, is developing a rapid, integrated point-of-care testing system to assess red blood cell sickling as an indicator of sickle cell disease (SCD) patient condition and treatment efficacy. The goal is to create a...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $299,995 Project Grant under the Cardiovascular Diseases Research (CFDA 93.837) program to Nanite Inc., a small disadvantaged business in Massachusetts. The grant will fund the development of computationally-designed polymer-based delivery vehicles for mRNA payloads to treat cystic fibrosis (CF), a debilitating genetic disorder affecting the lungs. The project aims to leverage computational modeling and high-throughput polymer...
This $299,504 Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of a novel therapeutic approach to clear small dense low-density lipoprotein (SDLDL) from circulation. The research aims to reengineer a proprietary APOC-III antagonist to include bioactive APOE mimetic peptides, creating a dual-domain therapeutic candidate that can bind APOC-III on SDLDL particles and...
This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $306,101 to Teucer Biotech, Inc. to develop a novel urinary biomarker assay that can predict the risk of cardiovascular disease (CVD) earlier and more accurately than existing methods. The key products and services to be delivered under this grant include: 1) Standardizing the RT-PCR-based assay to measure podocyte-specific mRNA...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $817,208 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Broad Institute, Inc. The grant will fund research to investigate the genetic basis and underlying mechanisms of heart failure using high-throughput cellular assays. The research aims to accelerate the functional interpretation of genes associated with heart failure risk identified through genome-wide association studies. The project...
The federal Project Grant award R01HL175892, funded by the National Heart Lung and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837), aims to develop and validate new technology for accurate, rapid, point-of-care, and high-frequency blood gas analysis. The $735,939 award supports two key objectives: 1) creating a miniaturized and automated device that attaches to an arterial catheter to enable direct sampling and immediate blood gas analysis at the bedside,...
The National Heart, Lung, and Blood Institute (NHLBI) awarded a $269,922 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Steth X Microsystems Inc. to develop a smart, wearable contact microphone patch for extended and remote monitoring of lung functions. The goal is to create a low-profile, battery-powered wireless device capable of accurately detecting and quantifying adventitious lung sounds as well as breathing abnormalities in patients with respiratory...